Article Text

Download PDFPDF

Combination radioimmunotherapy with adoptive NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma
  1. Robert Canter1,
  2. Steven K Grossenbacher1,
  3. Jiwon Sarah Park2,
  4. Jaime Modiano3,
  5. Erik Ames1,
  6. Stephanie Mac1,
  7. Arta M Monjazeb1,
  8. Michael Kent4,
  9. William Culp4,
  10. Mingyi Chen2 and
  11. William Murphy1
  1. Aff1 grid.27860.3b0000000419369684University of California, Davis Sacramento CA USA
  2. Aff2 grid.17635.360000000419368657University of Minnesota Minneapolis MN USA
  3. Aff3 grid.27860.3b0000000419369684UC Davis Comprehensive Cancer Center Sacramento CA USA
  4. Aff4 grid.27860.3b0000000419369684UC Davis School of Veterinary Medicine Davis CA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


We have previously shown that NK cells preferentially target cancer stem cells (CSCs) in diverse human solid malignancies and that radiotherapy (RT) enhances NK targeting of CSCs in an NKG2D-dependent manner. We hypothesized that dog PBMC-derived NK cells could be similarly expanded and activated ex vivo for combination radioimmunotherapy in canine models of sarcoma.


Dog NK cells were isolated from fresh PBMCs using Ficoll separation and CD5 depletion. Isolated NK cells (CD3+, CD5dim, TCR-) were expanded via co-culture with irradiated (100Gy) K562-C9-mIL-21 for 2-3 weeks in 100IU/mL recombinant human IL-2. Canine osteosarcoma (OSCA) tumor lines and fresh canine primary sarcomas were evaluated for susceptibility to NK killing before/after RT in vitro and in xenograft experiments with NSG mice. NK cytotoxicity was assessed in 4-16 hour killing assays by Flow cytometry using a BD Fortessa cell sorter (BD Biosciences) with 7-Aminoactinomycin as cell viability marker.


NK expansion was successful in 14/20 donors (including 9 tumor-bearing dogs) from baseline 4.5(±1.9) ×106 cells to 103.5(±29.1) ×106, mean increase 23.2X (±2.3). Canine NK cells were also responsive to human cytokines (IL-2, IL-12, and IL-18), but expansions were lower (1.6-3.5 fold expansion over 14 days). NK cytotoxicity to OSCA78, OSCA23, and NK-sensitive CTAC cells in vitro increased in a dose-dependent fashion reaching 74 – 88% cytolysis at effector:target ratios of 10:1 – 20:1 (P < 0.001). RT augmented NK cytotoxicity with greatest synergy at 2.5-5 Gy RT in 4-hour killing assays (1.3-3.4X increased killing, P < 0.01). At doses of 10 Gy and/or16-hour killing assays, only minor differences in overall killing were observed. Similar results were observed with RT sensitization to NK killing in primary canine sarcomas. In a dog sarcoma PDX model using focal RT, intravenous NK transfer, and hydrodynamic human IL-15 for in vivo NK support, focal RT increased NK homing to tumors by 3.8X±0.3 (P < 0.001).


RT enhances NK homing and killing in canine models of STS. Dog STS appears to be a valuable model to facilitate clinical translation of NK radioimmunotherapy.